Contract Service Directory

Recipharm





Company Headquarters

Box 603
Stockholm, 101 32
Sweden

Company Description

Recipharm is a leading contract development and manufacturing organisation (CDMO) headquartered in Stockholm, Sweden. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering for our customers. Employing around 7,000 people, we are focused on supporting pharmaceutical companies with our full service offering, taking products from early development through to commercial production. For over 20 years we have been there for our clients throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again. Despite our growing global footprint, we conduct our business as we always have and continue to deliver value for money with each customer’s needs firmly at the heart of all that we do. That’s the Recipharm way.

Contract Service Directory

    Content From Recipharm

    Related Content

    • Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      Recipharm, RedHill Biopharma Ink Commercial Mfg. Pact

      Recipharm, RedHill Biopharma Ink Commercial Mfg. Pact

      CDMO to provide commercial manufacturing to support Talicia launch following FDA approval.
      12.04.19

    • APIs | Breaking News | Drug Delivery | Drug Development | Industry News | Parenterals
      Recipharm Inks $650M Deal for Consort Medical

      Recipharm Inks $650M Deal for Consort Medical

      To become top five global CDMO.
      11.20.19

    • Drug Development | Drug Discovery
      Recipharm Joins AMR Industry Alliance

      Recipharm Joins AMR Industry Alliance

      Aims to address growing concerns around antimicrobial resistance.
      11.14.19


    • Breaking News | cGMP Manufacture | Industry News
      Recipharm Invests in Nichepharm Lifesciences

      Recipharm Invests in Nichepharm Lifesciences

      Partnership aims to create production capacity in India for a range of sterile dosage forms
      11.07.19

    • Bioanalytical Services | Clinical Trials | Industry News | Laboratory Testing
      Recipharm Divests Bioanalysis Biz

      Recipharm Divests Bioanalysis Biz

      Expands existing partnership with CTC Clinical Trial Consultants AB.
      11.04.19

    • Analytical Services | Industry News | QA/QC
      Recipharm Launches Recipharm Analytical Solutions

      Recipharm Launches Recipharm Analytical Solutions

      Stand-alone service offers analytical services including method development, method validation, and stability program design and implementation
      11.04.19


    • AAPS Exhibitor List

      Company Name Booth # 3D BIOOPTIMA CO., LTD. 1205 AbbVie 2639 AbbVie C1 ABITEC CORPORATION 628 Absorption Systems…
      10.29.19

    • PPD Expands Bioanalytical Lab Capabilities

      PPD Expands Bioanalytical Lab Capabilities

      Expansion includes growing the lab’s immunochemistry and biomarker space by 8,000 square feet
      09.19.19

    • Clinical Trials | CRO News | Drug Development
      QPS Expands Global Footprint

      QPS Expands Global Footprint

      Adds new facilities in The Netherlands and India
      09.19.19


    • Contracting And Outsourcing Exhibitor List

      2019 Exhibitors Company Table 3C PACKAGING 138 Adare Pharmaceuticals 97 Adents 123 Admix Pharma Labs 135 Advanced Analytical…
      09.17.19

    • APIs | Scale-up/Technology Transfer
      Drug Substances: Scale-Up Challenges

      Drug Substances: Scale-Up Challenges

      A look at the necessary steps and evaluations needed in order to manage complexities and reduce timelines.
      Anders Högdin, Senior Sales Director, Recipharm 09.16.19

    • Clinical Trials | CRO News | Drug Development
      AES Acquires Bioclinica

      AES Acquires Bioclinica's Clinical Research Site Biz

      Expands global footprint and position in patient access and site conduct
      09.06.19


    • Harbour BioMed, PPD to Develop Oncology and Immunology Therapeutics

      Harbour BioMed, PPD to Develop Oncology and Immunology Therapeutics

      Will focus on developing HBM4003, an anti-cancer immunotherapy to target solid tumors
      08.27.19

    • 05	Sanofi

      05 Sanofi

      Headquarters: Paris, France twitter.com/sanofi www.sanofi.com Headcount: 104,226 Year Established: 2004 Revenues:  $39,419   (-2%) Net Income:  $4,925  (+1%) R&D:  $6,742 (+8%) TOP SELLING DRUGS &n…
      07.15.19

    • 04	Johnson & Johnson

      04 Johnson & Johnson

      Headquarters: New Brunswick, NJ twitter.com/JNJComm www.jnj.com Headcount: 135,100 Revenues:  $81,581  (+7%) Pharma Revenues:  $40,734  (+12%) Net Income:  $15,297  (N/M) R&D:  $10,775  (+2%)…
      07.15.19

    • Ergomed Proposes Appointment of Former Chiltern CEO

      Ergomed Proposes Appointment of Former Chiltern CEO

      Dr. Jim Esinhart to be appointed as a Non-Executive Director of the Company
      07.10.19

    • Breaking News | Facilities | Industry News | Solid Dosage/Creams/Ointments
      Tergus to Build Commercial Manufacturing Facility

      Tergus to Build Commercial Manufacturing Facility

      Adds commercial capabilities and will expand current capacity by 400%
      06.12.19